Aldeyra Therapeutics (NASDAQ:ALDX) Earns Neutral Rating from HC Wainwright

Aldeyra Therapeutics (NASDAQ:ALDX)‘s stock had its “neutral” rating reaffirmed by HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $2.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 61.94% from the stock’s current price.

Several other equities research analysts also recently weighed in on ALDX. Wall Street Zen downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. BTIG Research reaffirmed a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday. Finally, Weiss Ratings downgraded Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, September 14th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $5.50.

Aldeyra Therapeutics Price Performance

ALDX stock traded down $0.09 during trading on Wednesday, reaching $1.24. 1,066,436 shares of the stock traded hands, compared to its average volume of 1,755,981. The business’s 50 day moving average price is $1.48 and its 200-day moving average price is $1.73. Aldeyra Therapeutics has a 52-week low of $1.07 and a 52-week high of $5.93. The firm has a market capitalization of $74.51 million, a PE ratio of -3.17 and a beta of 1.20.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). On average, equities research analysts predict that Aldeyra Therapeutics will post -0.39 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. 683 Capital Management LLC lifted its stake in shares of Aldeyra Therapeutics by 86.6% in the fourth quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock worth $7,925,000 after acquiring an additional 710,000 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Aldeyra Therapeutics in the second quarter worth about $2,678,000. Kennedy Capital Management LLC lifted its stake in shares of Aldeyra Therapeutics by 12.9% in the fourth quarter. Kennedy Capital Management LLC now owns 1,255,838 shares of the biotechnology company’s stock worth $6,505,000 after acquiring an additional 143,625 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Aldeyra Therapeutics by 146.6% in the first quarter. Renaissance Technologies LLC now owns 863,187 shares of the biotechnology company’s stock worth $1,459,000 after acquiring an additional 513,187 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Aldeyra Therapeutics by 1.9% in the first quarter. Dimensional Fund Advisors LP now owns 624,170 shares of the biotechnology company’s stock worth $1,055,000 after acquiring an additional 11,912 shares in the last quarter. Institutional investors and hedge funds own 59.71% of the company’s stock.

Key Stories Impacting Aldeyra Therapeutics

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Positive Sentiment: Aldeyra intends to submit a formal dispute resolution request to the FDA regarding reproxalap. The action gives the company an opportunity to contest the agency’s position and potentially advance the dry-eye program, which had prompted a rally in shares previously. Aldeyra Announces Intent to Submit Formal Dispute Resolution Request
• Positive Sentiment: BTIG Research reaffirmed its “buy” rating on ALDX, indicating that the analyst sees potential value despite the regulatory challenges.
• Neutral Sentiment: HC Wainwright reaffirmed its “neutral” rating and set a $2.00 price target, implying substantial upside from recent trading levels but signaling a cautious view of the risk-reward profile.
• Negative Sentiment: The dispute request follows a third FDA complete response letter for reproxalap. Until the FDA accepts or resolves the company’s appeal, the timing and likelihood of approval remain unclear, limiting investor confidence. Aldeyra Plans FDA Dispute Resolution Request After Third Complete Response Letter

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research centers on reactive aldehyde species, or RASP, which are inflammatory mediators that can contribute to tissue damage and disease progression.

Aldeyra’s lead investigational product is reproxalap, a small-molecule RASP inhibitor being developed for ocular conditions, including dry eye disease and allergic conjunctivitis. The company has also developed ADX-2191, an investigational intravitreal formulation of methotrexate intended for the treatment of certain rare retinal diseases, including proliferative vitreoretinopathy and retinitis pigmentosa.

Founded in 2008 and headquartered in Lexington, Massachusetts, Aldeyra conducts its research and clinical development activities primarily in the United States.